Wuhan HealthCare Biotechnology Co., Ltd.

Wuhan HealthCare Biotechnology Co., Ltd. granted 30 million of capital financing 

Wuhan HealthCare Biotechnology Co., Ltd. products and services are mainly used in cardio-cerebrovascular, tumor, cancer and other major diseases. Its business scope includes pharmacogenomics detection kit, rapid fluorescence in situ hybridization probe kit and its equipment development, production and sales. Since its inception, the company has obtained more than 10 invention patents, and developed a fully independent intellectual property rights fluorescent quantitative PCR, multiplex PCR and FastProbe® technology platform. In 2017, the pharmacogenomics CYP2C19, VKORC1 & CYP2C9 two products have been CFDA Class III and CE registered; fast fluorescent in situ hybridization probes ALK, HER2 have achieved CE registration and CFDA Class III certification is under finalization. The company has self-developed FastProbe® fluorescent in situ hybridization probes to break through many years of technical bottlenecks in the field, successfully reducing the sample hybridization time from the traditional overnight hybridization to 2 hours. At present, the company's cancer product line has assembled more than 200 probe reagents, including solid tumors and blood diseases.

HealthCare Biotech present grant is the trust the company is benefiting and a recognition of its great contribution in the field, to the China’s health care industry and will use this round of financing to carry out and strengthen its product line R&D, production and sales promotion. The company is currently developing a fully automatic fluorescence in situ hybridization device that will revolutionise and free the FISH detection technology from manual operation to fully automatic procedure. With HealthCare Biotech's FastProbe® probes, full automation and rapid detection in FISH can be completed expeditiously.